BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...

January 27, 2025 | News

Akeso Secures CDE Approval for IL-17 Monoclonal Antibody Gumokimab to Address Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting mon...

January 27, 2025 | News

Kelun-Biotech Secures NMPA Approval for Tagitanlimab in First-Line Treatment of Nasopharyngeal Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from Natio...

January 24, 2025 | News

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

January 24, 2025 | News

GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy

GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...

January 23, 2025 | News

Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers

Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...

January 23, 2025 | News

Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...

January 22, 2025 | News

YolTech Therapeutics Launches Clinical Trial for YOLT-204 a First-in-Class Gene Editing Therapy for Beta-Thalassemia

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for Y...

January 21, 2025 | News

Medidata Leads the Way in Sustainable Clinical Trials with EU Taxonomy Certification

-Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that Medid...

January 17, 2025 | News

Nextbiomedical Secures FDA IDE Approval for U.S. Clinical Trial of Nexsphere-F™ in Knee Osteoarthritis

NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Devi...

January 16, 2025 | News

Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | News

ImmunityBio Advances Marketing Authorization Applications for BCG-Unresponsive NMIBC CIS in Europe and the UK

Marketing authorization application for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in situ (CIS) submitted to Europ...

January 16, 2025 | News

Lyndra Partners with Thermo Fisher to Drive Phase 3 Trials and Commercial Manufacturing of Long-Acting Oral Therapies

Leveraging its Accelerator™ Drug Development, 360° CDMO and CMO solutions, Thermo Fisher will provide clinical research services for Lyndra...

January 16, 2025 | News

China Approves Sarclisa-Pd for Relapsed Multiple Myeloma, Backed by Pivotal Trial and Real-World Data.

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa ...

January 13, 2025 | News

Stay Connected